Cart
sales@molnova.com
Umbralisib
CAS No. 1532533-67-7
Umbralisib ( RP 5264;TGR1202;TGR-1202 )
Catalog No. M12154 CAS No. 1532533-67-7
Umbralisib (RP5264,TGR1202, TGR-1202) is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 53 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 324 | In Stock |
|
| 50MG | 426 | In Stock |
|
| 100MG | 624 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUmbralisib
-
NoteResearch use only, not for human use.
-
Brief DescriptionUmbralisib (RP5264,TGR1202, TGR-1202) is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.
-
DescriptionUmbralisib (RP5264,TGR1202, TGR-1202) is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM, 50-fold selectivity over PI3Kα/β and >10,000 fold over PI3Kγ; enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest, demonstrates highly synergistic effect with the proteasome inhibitor carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells; synergistically disrupts the 4E-BP1-eIF4F-c-Myc axis with carfilzomib, also potently inhibits 60% of the activity of CK1ε at 1 uM.Blood Cancer Phase 3 Clinical
-
SynonymsRP 5264;TGR1202;TGR-1202
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kδ
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1532533-67-7
-
Formula Weight571.55
-
Molecular FormulaC31H24F3N5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16
-
Chemical Name4H-1-Benzopyran-4-one, 2-[(1S)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Locatelli SL, et al. Leukemia. 2016 Dec;30(12):2402-2405.
2. Deng C, et al. Blood. 2017 Jan 5;129(1):88-99.
3. Burris HA 3rd, et al. Lancet Oncol. 2018 Feb 20. pii: S1470-2045(18)30082-2.
2. Deng C, et al. Blood. 2017 Jan 5;129(1):88-99.
3. Burris HA 3rd, et al. Lancet Oncol. 2018 Feb 20. pii: S1470-2045(18)30082-2.
molnova catalog
related products
-
PI3K-IN-16
PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.
-
Duvelisib (R enantio...
Duvelisib R enantiomer is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.
-
Seletalisib
Seletalisib (UCB-5857)is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM.
